nach oben

Tumor Biology

Erschienen in:

05.08.2016 | Original Article

Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression

verfasst von: Ying Zhu, Liqiong Cai, Jing Guo, Na Chen, Xiaoqing Yi, Yong Zhao, Jing Cai, Zehua Wang

Erschienen in: Tumor Biology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Dicer is an essential component of the microRNA (miRNA) processing machinery whose low expression is associated with advanced stage and poor clinical outcome in epithelial ovarian cancer. To investigate the functional relevance of Dicer in epithelial ovarian cancer and to identify its downstream effectors, two-dimensional gel electrophoresis combined with mass spectrometry was used for proteomic profiling. Dicer depletion promoted ovarian cancer cell proliferation and migration accompanied by a global upregulation of proteins. Twenty-six proteins, 7 upregulated and 19 downregulated, were identified. The functions of the identified proteins and their interactions were bioinformatically analyzed. Among them, protein disulfide-isomerase A3 (PDIA3) was considered to be a potential target protein of Dicer. PDIA3 repression by siRNA could significantly relieve the proliferation- and migration-promoting effect mediated by Dicer depletion in vitro and in vivo. Moreover, the miRNAs targeting PDIA3 were decreased in cells with Dicer depletion. In summary, low Dicer expression contributes to epithelial ovarian cancer progression by elevating PDIA3 expression.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMed

Merritt WM, Bar-Eli M, Sood AK. The dicey role of Dicer: implications for RNAi therapy. Cancer Res. 2010;70:2571–4.CrossRefPubMedPubMedCentral

Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3–14.CrossRefPubMedPubMedCentral

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.CrossRefPubMed

Wu JF, Shen W, Liu NZ, Zeng GL, Yang M, Zuo GQ, Gan XN, Ren H, Tang KF. Down-regulation of Dicer in hepatocellular carcinoma. Med Oncol. 2011;28:804–9.CrossRefPubMed

Poursadegh Zonouzi AA, Nejatizadeh A, Rahmati-Yamchi M, Fardmanesh H, Shakerizadeh S, Poursadegh Zonouzi A, Nejati-Koshki K, Shekari M. Dysregulated expression of Dicer in invasive ductal breast carcinoma. Med Oncol. 2015;32:203.CrossRefPubMed

Zhang J, Zhang XH, Wang CX, Liu B, Fan XS, Wen JJ, Shi QL, Zhou XJ. Dysregulation of microRNA biosynthesis enzyme Dicer plays an important role in gastric cancer progression. Int J Clin Exp Pathol. 2014;7:1702–7.PubMedPubMedCentral

Zhao H, Jin X, Su H, Deng X, Fang Y, Shen L, Xie C. Down-regulation of Dicer expression in cervical cancer tissues. Med Oncol. 2014;31:937.CrossRefPubMed

Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G. Down-regulation of Dicer expression in ovarian cancer tissues. Clin Biochem. 2010;43:324–7.CrossRefPubMed

10.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008;359:2641–50.CrossRefPubMedPubMedCentral

11.

Faggad A, Budczies J, Tchernitsa O, Darb-Esfahani S, Sehouli J, Muller BM, Wirtz R, Chekerov R, Weichert W, Sinn B, Mucha C, Elwali NE, Schafer R, Dietel M, Denkert C. Prognostic significance of dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J Pathol. 2010;220:382–91.PubMed

12.

Kuang Y, Cai J, Li D, Han Q, Cao J, Wang Z. Repression of Dicer is associated with invasive phenotype and chemoresistance in ovarian cancer. Oncol Lett. 2013;5:1149–54.PubMedPubMedCentral

13.

Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A. 2012;109:3921–6.CrossRefPubMedPubMedCentral

14.

Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L, Wang Z. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther. 2010;10:788–95.CrossRefPubMed

15.

Zhou J, Cai J, Huang Z, Ding H, Wang J, Jia J, Zhao Y, Huang D, Wang Z. Proteomic identification of target proteins following Drosha knockdown in cervical cancer. Oncol Rep. 2013;30:2229–37.PubMed

16.

Zhao S, Wen Z, Liu S, Liu Y, Li X, Ge Y, Li S. MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3. Mol Med Rep. 2015;12:3923–9.PubMed

17.

Comegna M, Succoio M, Napolitano M, Vitale M, D’Ambrosio C, Scaloni A, Passaro F, Zambrano N, Cimino F, Faraonio R. Identification of mir-494 direct targets involved in senescence of human diploid fibroblasts. FASEB J Off Publ Fed Am Soc Exp Biol. 2014;28:3720–33.

18.

Ma X, Fan Y, Gao Y, Zhang Y, Huang Q, Ai Q, Ni D, Chen W, Zhang P, Song E, Wang B, Shi T, Zheng T, Zhang X. Dicer is down-regulated in clear cell renal cell carcinoma and in vitro dicer knockdown enhances malignant phenotype transformation. Urol Oncol. 2014;32:46 e49–17.CrossRef

19.

Zeng S, Yang J, Zhao J, Liu Q, Rong M, Guo Z, Gao W. Silencing Dicer expression enhances cellular proliferative and invasive capacities in human tongue squamous cell carcinoma. Oncol Rep. 2014;31:867–73.PubMed

20.

Muller PA, Trinidad AG, Caswell PT, Norman JC, Vousden KH. Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype. J Biol Chem. 2014;289:122–32.CrossRefPubMed

21.

Iliou MS, da Silva-Diz V, Carmona FJ, Ramalho-Carvalho J, Heyn H, Villanueva A, Munoz P, Esteller M. Impaired dicer1 function promotes stemness and metastasis in colon cancer. Oncogene. 2014;33:4003–15.CrossRefPubMed

22.

Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, Dhir R. Up-regulation of Dicer, a component of the microRNA machinery, in prostate adenocarcinoma. Am J Pathol. 2006;169:1812–20.CrossRefPubMedPubMedCentral

23.

Muralidhar B, Goldstein LD, Ng G, Winder DM, Palmer RD, Gooding EL, Barbosa-Morais NL, Mukherjee G, Thorne NP, Roberts I, Pett MR, Coleman N. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J Pathol. 2007;212:368–77.CrossRefPubMed

24.

Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, Ando T, Mori R, Takashima N, Ogawa R, Fujii Y. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:7322–8.CrossRef

25.

Zhang B, Chen H, Zhang L, Dakhova O, Zhang Y, Lewis MT, Creighton CJ, Ittmann MM, Xin L. A dosage-dependent pleiotropic role of dicer in prostate cancer growth and metastasis. Oncogene. 2014;33:3099–108.CrossRefPubMed

26.

Kurzynska-Kokorniak A, Koralewska N, Pokornowska M, Urbanowicz A, Tworak A, Mickiewicz A, Figlerowicz M. The many faces of Dicer: the complexity of the mechanisms regulating dicer gene expression and enzyme activities. Nucleic Acids Res. 2015;43:4365–80.CrossRefPubMedPubMedCentral

27.

Coppari S, Altieri F, Ferraro A, Chichiarelli S, Eufemi M, Turano C. Nuclear localization and DNA interaction of protein disulfide isomerase ERp57 in mammalian cells. J Cell Biochem. 2002;85:325–33.CrossRefPubMed

28.

Turano C, Gaucci E, Grillo C, Chichiarelli S. ERp57/GRP58: a protein with multiple functions. Cell Mol Biol Lett. 2011;16:539–63.CrossRefPubMed

29.

Chichiarelli S, Ferraro A, Altieri F, Eufemi M, Coppari S, Grillo C, Arcangeli V, Turano C. The stress protein ERp57/GRP58 binds specific DNA sequences in HeLa cells. J Cell Physiol. 2007;210:343–51.CrossRefPubMed

30.

Eufemi M, Coppari S, Altieri F, Grillo C, Ferraro A, Turano C. ERp57 is present in STAT3-DNA complexes. Biochem Biophys Res Commun. 2004;323:1306–12.CrossRefPubMed

31.

Hirano N, Shibasaki F, Sakai R, Tanaka T, Nishida J, Yazaki Y, Takenawa T, Hirai H. Molecular cloning of the human glucose-regulated protein ERp57/GRP58, a thiol-dependent reductase. Identification of its secretory form and inducible expression by the oncogenic transformation. Eur j Biochem FEBS. 1995;234:336–42.CrossRef

32.

Celli CM, Jaiswal AK. Role of GRP58 in mitomycin c-induced DNA cross-linking. Cancer Res. 2003;63:6016–25.PubMed

33.

Santana-Codina N, Carretero R, Sanz-Pamplona R, Cabrera T, Guney E, Oliva B, Clezardin P, Olarte OE, Loza-Alvarez P, Mendez-Lucas A, Perales JC, Sierra A. A transcriptome-proteome integrated network identifies endoplasmic reticulum thiol oxidoreductase (ERp57) as a hub that mediates bone metastasis. Mol Cell Proteomics MCP. 2013;12:2111–25.CrossRefPubMed

34.

Liao CJ, Wu TI, Huang YH, Chang TC, Wang CS, Tsai MM, Lai CH, Liang Y, Jung SM, Lin KH. Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer. Cancer Sci. 2011;102:2255–63.CrossRefPubMed

35.

Cicchillitti L, Di Michele M, Urbani A, Ferlini C, Donat MB, Scambia G, Rotilio D. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780tc1 by 2D-DIGE: the role of ERp57. J Proteome Res. 2009;8:1902–12.CrossRefPubMed

36.

Chichiarelli S, Gaucci E, Ferraro A, Grillo C, Altieri F, Cocchiola R, Arcangeli V, Turano C, Eufemi M. Role of ERp57 in the signaling and transcriptional activity of STAT3 in a melanoma cell line. Arch Biochem Biophys. 2010;494:178–83.CrossRefPubMed

37.

Liao CJ, Wu TI, Huang YH, Chang TC, Lai CH, Jung SM, Hsueh C, Lin KH. Glucose-regulated protein 58 modulates beta-catenin protein stability in a cervical adenocarcinoma cell line. BMC Cancer. 2014;14:555.CrossRefPubMedPubMedCentral

38.

Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:1005–14.CrossRef

39.

Anastas JN, Moon RT. Wnt signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.CrossRefPubMed

40.

Tan FH, Putoczki TL, Stylli SS, Luwor RB. The role of STAT3 signaling in mediating tumor resistance to cancer therapy. Curr Drug Targets. 2014;15:1341–53.CrossRefPubMed

Titel: Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression
verfasst von: Ying Zhu
Liqiong Cai
Jing Guo
Na Chen
Xiaoqing Yi
Yong Zhao
Jing Cai
Zehua Wang
Publikationsdatum: 05.08.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 10/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5218-4

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2016

Tescalcin expression contributes to invasive and metastatic activity in colorectal cancer

PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT

Mechanisms underlying the association between obesity and Hodgkin lymphoma

Fibronectin protects lung cancer cells against docetaxel-induced apoptosis by promoting Src and caspase-8 phosphorylation

Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L

Erratum to: Secretome of tumor-associated leukocytes augment epithelial-mesenchymal transition in positive lymph node breast cancer patients via activation of EGFR/Tyr845 and NF-kB/p65 signaling pathway

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie